NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 125,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the transaction, the insider owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $27.34 on Wednesday. The stock has a market capitalization of $3.27 billion, a PE ratio of -12.66 and a beta of 0.10. The company has a fifty day moving average of $30.53 and a 200-day moving average of $32.07. NewAmsterdam Pharma Company N.V. has a one year low of $23.05 and a one year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. Equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its position in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. KBC Group NV acquired a new stake in shares of NewAmsterdam Pharma in the first quarter valued at approximately $37,000. Navalign LLC purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $46,000. Finally, AdvisorNet Financial Inc purchased a new position in shares of NewAmsterdam Pharma during the 1st quarter worth approximately $82,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Royal Bank Of Canada decreased their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Finally, BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $49.73.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.